Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease


Ageing and inflammation strongly drive the risk of cardiovascular disease. Work over the past decade has uncovered a common condition characterized by the positive selection of certain somatic mutations in haematopoietic stem cells in ageing humans. This phenomenon, known as clonal haematopoiesis of indeterminate potential (CHIP), occurs most commonly as a result of mutations in the transcriptional regulators DNMT3A, TET2 and ASXL1. CHIP is associated with a variety of adverse outcomes, including haematological cancer and death. Surprisingly, CHIP is also associated with a doubling of the risk of atherosclerotic cardiovascular disease. Studies in mice support the causality of this relationship. Mutations in TET2, which are among the most commonly found mutations in CHIP, lead to increased expression of inflammatory genes in innate immune cells, potentially explaining the link between mutations and increased cardiovascular risk. Therapies targeting the mutant clones or the increased inflammatory mediators might be useful for ameliorating the risk of cardiovascular disease. We propose that the mutations leading to clonal haematopoiesis contribute to the increased inflammation seen in ageing and thereby explain some of the age-related risk of cardiovascular disease.

Key points

  • Clonal haematopoiesis of indeterminate potential (CHIP) is a common age-related condition characterized by the clonal expansion of haematopoietic stem cells bearing mutations in certain genes, especially DNMT3A, TET2 and ASXL1.

  • CHIP is associated with increased risk of haematological malignancies and all-cause mortality, but also increased risk of atherosclerotic cardiovascular disease, venous thrombosis and worse outcomes in heart failure.

  • Mutations associated with CHIP seem to have effects on immune effector cells, such as macrophages and neutrophils, which might account for the increased risk of cardiovascular complications in individuals with CHIP.

  • No treatments are currently available to lower the risk of cardiovascular disease in those with CHIP, but blockade of inflammatory molecules is a potential strategy to mitigate the effects of CHIP.

  • Individuals incidentally found to have CHIP should undergo evaluation for lifestyle modifications to reduce the risk of cardiovascular disease.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Cardiovascular conditions related to CHIP-associated mutations.
Fig. 2: Mutational spectrum and prevalence of clonal haematopoiesis.


  1. 1.

    Wang, T. J. et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 355, 2631–2639 (2006).

  2. 2.

    Pencina, M. J., D’Agostino, R. B. Sr, Larson, M. G., Massaro, J. M. & Vasan, R. S. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 119, 3078–3084 (2009).

  3. 3.

    Sniderman, A. D. & Furberg, C. D. Age as a modifiable risk factor for cardiovascular disease. Lancet 371, 1547–1549 (2008).

  4. 4.

    Lloyd-Jones, D. M. et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113, 791–798 (2006).

  5. 5.

    Libby, P., Nahrendorf, M. & Swirski, F. K. Leukocytes link local and systemic inflammation in ischemic cardiovascular disease: an expanded “cardiovascular continuum”. J. Am. Coll. Cardiol. 67, 1091–1103 (2016).

  6. 6.

    Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).

  7. 7.

    Wikby, A. et al. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech. Ageing Dev. 127, 695–704 (2006).

  8. 8.

    Ferrucci, L. et al. The origins of age-related proinflammatory state. Blood 105, 2294–2299 (2005).

  9. 9.

    Furman, D. et al. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nat. Med. 23, 174–184 (2017).

  10. 10.

    Franceschi, C. & Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A Biol. Sci. Med. Sci. 69 (Suppl. 1), 4–9 (2014).

  11. 11.

    Franceschi, C. et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N. Y. Acad. Sci. 908, 244–254 (2000).

  12. 12.

    Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).

  13. 13.

    Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).

  14. 14.

    Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472–1478 (2014).

  15. 15.

    Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017).

  16. 16.

    Zhang, Q. et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525, 389–393 (2015).

  17. 17.

    Fuster, J. J. et al. Clonal hematopoiesis associated with Tet2 deficiency accelerates atherosclerosis development in mice. Science 355, 842–847 (2017).

  18. 18.

    Moore, K. J. et al. Macrophage trafficking, inflammatory resolution, and genomics in atherosclerosis: JACC Macrophage in CVD Series (Part 2). J. Am. Coll. Cardiol. 72, 2181–2197 (2018).

  19. 19.

    Schumski, A., Winter, C., Doring, Y. & Soehnlein, O. The ins and outs of myeloid cells in atherosclerosis. J. Innate Immun. 10, 479–486 (2018).

  20. 20.

    Doring, Y., Soehnlein, O. & Weber, C. Neutrophil extracellular traps in atherosclerosis and atherothrombosis. Circ. Res. 120, 736–743 (2017).

  21. 21.

    Franck, G. et al. Roles of PAD4 and NETosis in experimental atherosclerosis and arterial injury: implications for superficial erosion. Circ. Res. 123, 33–42 (2018).

  22. 22.

    Ridker, P. M. A test in context: high-sensitivity C-reactive protein. J. Am. Coll. Cardiol. 67, 712–723 (2016).

  23. 23.

    Armitage, P. & Doll, R. A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br. J. Cancer 11, 161–169 (1957).

  24. 24.

    Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264–278 (2012).

  25. 25.

    Martincorena, I. & Campbell, P. J. Somatic mutation in cancer and normal cells. Science 349, 1483–1489 (2015).

  26. 26.

    Abkowitz, J. L., Catlin, S. N., McCallie, M. T. & Guttorp, P. Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. Blood 100, 2665–2667 (2002).

  27. 27.

    Lee-Six, H. et al. Population dynamics of normal human blood inferred from somatic mutations. Nature 561, 473–478 (2018).

  28. 28.

    Nowell, P. C. The minute chromosome (Phl) in chronic granulocytic leukemia. Blut 8, 65–66 (1962).

  29. 29.

    Rowley, J. D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290–293 (1973).

  30. 30.

    Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23–28 (1976).

  31. 31.

    Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001).

  32. 32.

    Fey, M. F. et al. Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probe. Blood 83, 931–938 (1994).

  33. 33.

    Busque, L. et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood 88, 59–65 (1996).

  34. 34.

    Champion, K. M., Gilbert, J. G., Asimakopoulos, F. A., Hinshelwood, S. & Green, A. R. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J. Haematol. 97, 920–926 (1997).

  35. 35.

    Busque, L. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179–1181 (2012).

  36. 36.

    Sperling, A. S., Gibson, C. J. & Ebert, B. L. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat. Rev. Cancer 17, 5–19 (2017).

  37. 37.

    Jan, M., Ebert, B. L. & Jaiswal, S. Clonal hematopoiesis. Semin. Hematol. 54, 43–50 (2017).

  38. 38.

    Bowman, R. L., Busque, L. & Levine, R. L. Clonal hematopoiesis and evolution to hematopoietic malignancies. Cell Stem Cell 22, 157–170 (2018).

  39. 39.

    McKerrell, T. et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 10, 1239–1245 (2015).

  40. 40.

    Acuna-Hidalgo, R. et al. Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life. Am. J. Hum. Genet. 101, 50–64 (2017).

  41. 41.

    Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21, 374–382.e4 (2017).

  42. 42.

    Young, A. L., Challen, G. A., Birmann, B. M. & Druley, T. E. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat. Commun. 7, 12484 (2016).

  43. 43.

    Gibson, C. J. et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J. Clin. Oncol. 35, 1598–1605 (2017).

  44. 44.

    Zink, F. et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 130, 742–752 (2017).

  45. 45.

    Buscarlet, M. et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood 130, 753–762 (2017).

  46. 46.

    Abelson, S. et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559, 400–404 (2018).

  47. 47.

    Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9–16 (2015).

  48. 48.

    Desai, P. et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat. Med. 24, 1015–1023 (2018).

  49. 49.

    Sellar, R. S., Jaiswal, S. & Ebert, B. L. Predicting progression to AML. Nat. Med. 24, 904–906 (2018).

  50. 50.

    Tonelli, M. et al. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation 117, 163–168 (2008).

  51. 51.

    Patel, K. V., Ferrucci, L., Ershler, W. B., Longo, D. L. & Guralnik, J. M. Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch. Intern. Med. 169, 515–523 (2009).

  52. 52.

    Perlstein, T. S., Weuve, J., Pfeffer, M. A. & Beckman, J. A. Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch. Intern. Med. 169, 588–594 (2009).

  53. 53.

    Lippi, G. et al. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch. Pathol. Lab. Med. 133, 628–632 (2009).

  54. 54.

    Gerszten, R. E. et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398, 718–723 (1999).

  55. 55.

    Dorsheimer, L. et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 4, 25–33 (2019).

  56. 56.

    Morgan, K. J. & Gilliland, D. G. A role for JAK2 mutations in myeloproliferative diseases. Annu. Rev. Med. 59, 213–222 (2008).

  57. 57.

    Marchioli, R. et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J. Clin. Oncol. 23, 2224–2232 (2005).

  58. 58.

    Hinds, D. A. et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood 128, 1121–1128 (2016).

  59. 59.

    Carobbio, A. et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109, 2310–2313 (2007).

  60. 60.

    Landolfi, R. et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109, 2446–2452 (2007).

  61. 61.

    Wolach, O. et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci. Transl Med. 10, eaan8292 (2018).

  62. 62.

    Sano, S. et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. J. Am. Coll. Cardiol. 71, 875–886 (2018).

  63. 63.

    Sano, S. et al. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ. Res. 123, 335–341 (2018).

  64. 64.

    Wang, W. et al. Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 (V617F) mice. Circ. Res. 123, e35–e47 (2018).

  65. 65.

    Liu, D. J. et al. Exome-wide association study of plasma lipids in >300,000 individuals. Nat. Genet. 49, 1758–1766 (2017).

  66. 66.

    van Vlijmen, B. J. et al. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ. Res. 88, 780–786 (2001).

  67. 67.

    Merched, A. J., Williams, E. & Chan, L. Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler. Thromb. Vasc. Biol. 23, 1608–1614 (2003).

  68. 68.

    Svensson, E. C. et al. TET2-driven clonal hematopoiesis predicts enhanced response to canakinumab in the CANTOS trial: an exploratory analysis [abstract 15111]. Circulation 138 (Suppl. 1), A15111 (2018).

  69. 69.

    Leoni, C. et al. Dnmt3a restrains mast cell inflammatory responses. Proc. Natl. Acad. Sci. USA 114, E1490–E1499 (2017).

  70. 70.

    Coombs, C. C. et al. Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays. Clin. Cancer Res. 24, 5918–5924 (2018).

  71. 71.

    Guryanova, O. A. et al. Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. Leukemia 30, 1133–1142 (2016).

  72. 72.

    Cole, C. B. et al. Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. J. Clin. Invest. 127, 3657–3674 (2017).

  73. 73.

    Abdel-Wahab, O. et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J. Exp. Med. 210, 2641–2659 (2013).

  74. 74.

    Obeng, E. A. et al. Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation. Cancer Cell 30, 404–417 (2016).

  75. 75.

    Shirai, C. L. et al. Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo. Cancer Cell 27, 631–643 (2015).

  76. 76.

    Kim, E. et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27, 617–630 (2015).

  77. 77.

    Sun, B. et al. Phosphatase Wip1 negatively regulates neutrophil migration and inflammation. J. Immunol. 192, 1184–1195 (2014).

Download references


The authors were supported by Burroughs Wellcome Fund Career Award for Medical Scientists and Fondation Leducq Transatlantic Network of Excellence (S.J.) and by the National Heart, Lung, and Blood Institute (R01HL080472), AHA (18CSA34080399) and the RRM Charitable Fund (P.L.).

Author information

Both authors wrote the manuscript, and reviewed and edited it before submission.

Correspondence to Siddhartha Jaiswal.

Ethics declarations

Competing interests

S.J. has filed patents related to the topic of this Review and is a consultant for GRAIL. P.L. is an unpaid consultant to, or is involved in clinical trials for, Amgen, AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Novartis, Pfizer, Sanofi-Regeneron and XBiotech. P.L. is a member of the scientific advisory board for Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, IFM Therapeutics, Kowa Pharmaceuticals, Medimmune, Novartis, Olatec Therapeutics and XBiotech.

Additional information

Peer review information

Nature Reviews Cardiology thanks F. Swirski and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark